SynAct Pharma (SYNACS) Stock Overview
A clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SYNACS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
SynAct Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 24.00 |
| 52 Week High | SEK 24.00 |
| 52 Week Low | SEK 24.00 |
| Beta | 1.14 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYNACS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | 1.9% |
| 1Y | n/a | 32.9% | 22.9% |
Return vs Industry: Insufficient data to determine how SYNACS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how SYNACS performed against the UK Market.
Price Volatility
| SYNACS volatility | |
|---|---|
| SYNACS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: SYNACS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine SYNACS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 8 | Jeppe Ovlesen | synactpharma.com |
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.
SynAct Pharma AB Fundamentals Summary
| SYNACS fundamental statistics | |
|---|---|
| Market cap | SEK 1.27b |
| Earnings (TTM) | -SEK 106.27m |
| Revenue (TTM) | n/a |
Is SYNACS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNACS income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 106.28m |
| Earnings | -SEK 106.27m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 18, 2026
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SYNACS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/29 12:06 |
| End of Day Share Price | 2025/10/01 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SynAct Pharma AB is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrik Ling | DNB Carnegie |
| Jyoti Prakash | Edison Investment Research |
| Carl Ramanius | Redeye |